Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Autoimmunity

• Publication date

  2007-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.JAUT.2007.02.013PMID 17419007
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin.

  2007cited by this paper
• The placental bed in pregnancies complicated by primary antiphospholipid syndrome.

  2006cited by this paper
• Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms

  2006cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper
• Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases

  2006cited by this paper
• Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor.

  2005cited by this paper
• Prevention of Acute Vascular Rejection by a Functionally Blocking Anti-C5 Monoclonal Antibody Combined with Cyclosporine

  2005cited by this paper
• Humoral autoimmunity against endothelium: theory or reality?

  2005cited by this paper
• TNF-α Is a Critical Effector and a Target for Therapy in Antiphospholipid Antibody-Induced Pregnancy Loss1

  2005cited by this paper
• Hemolytic uremic syndrome.

  2005cited by this paper
• Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia.

  2005cited by this paper
• Antiphospholipid antibodies as cause of pregnancy loss

  2004cited by this paper
• Pathogenic mechanisms of antiphospholipid syndrome: a new autoimmune disease

  2004cited by this paper
• Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients

  2004cited by this paper
• Expression of the components and regulatory proteins of the classical pathway of complement in normal and diseased synovium

  2004cited by this paper
• Complement and complement regulatory proteins as potential molecular targets for vascular diseases.

  2004cited by this paper
• Management of the obstetric antiphospholipid syndrome.

  2004cited by this paper
• C5a-induced gene expression in human umbilical vein endothelial cells.

  2004cited by this paper
• Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation

  2004cited by this paper
• The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies.

  2004cited by this paper
• Antiphospholipid antibodies: update on detection, pathophysiology, and treatment

  2004cited by this paper
• Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster.

  2003cited by this paper
• Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

  2003cited by this paper
• Antiphospholipid Antibodies Induce Monocyte Chemoattractant Protein-1 in Endothelial Cells1

  2002cited by this paper
• Complement C3 Activation Is Required for Antiphospholipid Antibody-induced Fetal Loss

  2002cited by this paper
• Anticardiolipin Antibody Assay: a Methodological Analysis for a better Consensus in Routine Determinations

  2001cited by this paper
• Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype.

  2001cited by this paper
• The identification of endothelial cell autoantigens.

  2000cited by this paper
• Experimental thrombosis and antiphospholipid antibodies: new insights.

  2000cited by this paper
• Complement activation after oxidative stress: role of the lectin complement pathway.

  2000cited by this paper
• Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss

  1999cited by this paper
• Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides.

  1999cited by this paper
• Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.

  1999cited by this paper
• Complement-induced expression of chemokine genes in endothelium: regulation by IL-1-dependent and -independent mechanisms.

  1998cited by this paper
• Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice.

  1998cited by this paper
• The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells.

  1998cited by this paper
• The Cytolytically Inactive Terminal Complement Complex Activates Endothelial Cells to Express Adhesion Molecules and Tissue Factor Procoagulant Activity

  1997cited by this paper
• Placental Thrombosis and Fetal Loss After Passive Transfer of Mouse Lupus Monoclonal or Human Polyclonal Anti‐Cardiolipin Antibodies in Pregnant Naive BALB/c Mice

  1995cited by this paper
• Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

  1995cited by this paper
• Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1.

  1995cited by this paper
• Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules.

  1995cited by this paper
• C5a-induced expression of P-selectin in endothelial cells.

  1994cited by this paper
• Antiphospholipid antibodies and complement activation in patients with cerebral ischemia.

  1992cited by this paper
• Human Umbilical Vein Endothelial Cells Synthesize Functional C3, C5, C6, C8 and C9 In Vitro

  1991cited by this paper
• Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex.

  1990cited by this paper
• Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss.

  1990cited by this paper
• Cardiolipin antibodies and null alleles of C4 in black Americans with systemic lupus erythematosus.

  1988cited by this paper
• The third component of complement is transcribed and secreted by cultured human endothelial cells.

  1987cited by this paper

• Revisiting antiphospholipid syndrome: A thrombo-inflammatory disorder beyond clotting.

  2026cites this paper
• Dysregulation of complement factor H in juvenile-onset systemic lupus erythematosus patients

  2021cites this paper
• Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases

  2021cites this paper
• Platelet-derived microparticles from recurrent miscarriage associated with antiphospholipid antibody syndrome influence behaviours of trophoblast and endothelial cells.

  2019cites this paper
• Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications

  2018cites this paper
• Obstetric antiphospholipid syndrome

  2018cites this paper
• Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome

  2018cites this paper
• Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort

  2018cites this paper
• Promising Treatment Alternatives

  2018cites this paper
• Neuropsychiatric Systemic Lupus Erythematosus

  2018cites this paper
• Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).

  2017cites this paper
• Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome—A Retrospective Analysis and a Review of Additional Treatment in Pregnancy

  2017cites this paper
• Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome—Biomarkers of the Disease and Biopharmaceuticals

  2017cites this paper
• The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome

  2017influential citation
• Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data

  2016cites this paper
• Intérêt du test de génération de thrombine dans le syndrome des antiphospholipides

  2016cites this paper
• Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives

  2016cites this paper
• Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature.

  2015cites this paper
• The Pathogenic Mechanisms for Antiphospholipid Antibodies (aPL)-Mediated Pregnancy Loss

  2015cites this paper
• Antiphospholipid antibody syndrome.

  2014cites this paper
• Role of the complement in pregnancy with antiphospholipid syndrome: mechanisms of pathogenesis and clinical aspects

  2013cites this paper
• Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications

  2013cites this paper
• Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?

  2012cites this paper
• Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome

  2012cites this paper
• Pathogenesis of the Antiphospholipid Syndrome

  2012cites this paper
• Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome

  2012cites this paper
• Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss.

  2012cites this paper
• The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity.

  2012cites this paper
• What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity?

  2012cites this paper
• Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome.

  2012cites this paper
• Acquired and inherited thrombophilia disorders in pregnancy.

  2011cites this paper
• Pathophysiology of the antiphospholipid antibody syndrome

  2011cites this paper
• Obstetric Antiphospholipid Syndrome: An Update on Pathophysiology and Management

  2011cites this paper
• Classical complement activation as a footprint for murine and human antiphospholipid antibody‐induced fetal loss

  2011cites this paper
• Tissue Factor, Blood Coagulation, and Beyond: An Overview

  2011cites this paper
• Pathogenesis of antiphospholipid syndrome: understanding the antibodies

  2011cites this paper
• Complement Activation and Pregnancy Failure

  2010cites this paper
• Autoimmunity and Recurrent Pregnancy Losses

  2010cites this paper
• Co-existence of paroxysmal nocturnal hemoglobinuria and antiphospholipid syndrome-A role for complement activation.

  2010cites this paper
• Is there an association between complement activation and antiphospholipid antibody-related thrombosis?

  2010cites this paper
• Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis.

  2009cites this paper
• Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients.

  2009cites this paper
• Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members.

  2009cites this paper
• Neonatal effects of maternal antiphospholipid syndrome

  2009cites this paper
• Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome?

  2009cites this paper
• Atherosclerosis and Autoimmunity

  2009cites this paper
• Impact of antiphosholipid biology in maternal Down syndrome screening

  2009cites this paper
• The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence.

  2009cites this paper
• Clinical Significance of Complement Deficiencies

  2009cites this paper
• Quantitative Abnormalities of Peripheral Blood Distinct T, B, and Natural Killer Cell Subsets and Clinical Findings in Obstetric Antiphospholipid Syndrome

  2009cites this paper
• Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?

  2009cites this paper
• Complement Cascade in Systemic Lupus Erythematosus

  2009cites this paper
• Pregnancy and Catastrophic Antiphospholipid Syndrome

  2009cites this paper
• Catastrophic Antiphospholipid Syndrome: Treatment, Prognosis, and the Risk of Relapse

  2009cites this paper
• European Forum on Antiphospholipid Antibodies: research in progress

  2009cites this paper
• Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies

  2009cites this paper
• The interplay between the antiphospholipid syndrome and systemic lupus erythematosus

  2009cites this paper
• Microthrombotic/Microangiopathic Manifestations of the Antiphospholipid Syndrome

  2009cites this paper
• Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic Mechanisms

  2008cites this paper
• Coexistence of the antiphospholipid syndrome and abdominal aortic aneurysm.

  2008cites this paper
• Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome.

  2008cites this paper
• Chocolate at heart: the anti-inflammatory impact of cocoa flavanols.

  2008cites this paper
• Bone marrow transplantation, refractory autoimmunity and the contributions of Susumu Ikehara.

  2008cites this paper
• Updating on the Pathogenic Mechanisms 5 of the Antiphospholipid Antibodies-Associated Pregnancy Loss

  2008cites this paper
• Autoantibodies as predictors of pregnancy complications.

  2008cites this paper
• Autoantibody explosion in antiphospholipid syndrome.

  2008cites this paper
• Whither Autoimmunity: The Lessons of Anti-CCP and B cell Depletion

  2008cites this paper
• Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity.

  2008cites this paper
• Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies.

  2008cites this paper
• Systemic Lupus Erythematosus Involving the Nervous System: Presentation, Pathogenesis, and Management

  2008cites this paper
• One year in autoimmunity.

  2007cites this paper
• APS—More Systemic Disease than SLE

  2007cites this paper
• Annals of the New York Academy of Sciences: Foreword

  2007cites this paper
• Antiphospholipid syndrome dilemmas still to be solved: 2008 status

  2007cites this paper
• Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome.

  2007cites this paper
• Insights into atherosclerosis therapy in antiphospholipid syndrome.

  2007cites this paper
• syndrome dilemmas still to be solved: 2008 status

  year unknowncites this paper